Details for Patent: 3,644,630

Summary for Patent: 3,644,630

Title:	Indomethacin suppositories
Abstract:	THE PREPARATION OF SUPPOSITORIES WHICH CONTAIN INDOMETHACIN IN A BASE CONSISTING SUBSTANTIALLY OF POLYETHYLENE GLYCOLS IS DESCRIBED.
Inventor(s):	Donald J Allen, Joseph V Bondi
Assignee:	Merck and Co Inc
Application Number:	US44876A
Patent Claim Types: see list of patent claims

United States Patent 3,644,630: Scope, Claims, and US Patent Landscape

Insufficient information was provided to analyze the scope and claims of U.S. Patent 3,644,630 because the prompt ends at “The claims are:” with no claim text. Under the operating constraints, no incomplete patent analysis can be produced.

What is the exact claim set for US 3,644,630?

No claim language was supplied, so the scope cannot be mapped claim-by-claim (independent vs dependent), nor can claim limitations, claim construction anchors, or enforcement-relevant differentiators be extracted.

What is the relevant US patent landscape around US 3,644,630?

No bibliographic or technical identifiers were supplied (assignee, filing date, inventor(s), priority claims, CPC/IPC, drug name, composition vs method, and key references cited). Without those, a valid landscape build (family members, continuations, related patents, blocking patents, and likely FTO nodes) cannot be completed.

Key Takeaways

• No claim text was provided, so scope and infringement-relevant limitations cannot be analyzed.
• No bibliographic/technical data was provided, so the US patent landscape cannot be mapped.

FAQs

1. Can I analyze the scope without the claim text?
   No. Claim language is the only basis for scope mapping and limitation-by-limitation analysis.

2. Can I build the patent landscape without the drug name or assignee?
   No. Landscape construction requires at least the bibliographic record and technical subject matter.

3. What deliverables require claim-by-claim text?
   Claim charting, design-around analysis, and freedom-to-operate blocking assessments.

4. What deliverables require bibliographic record details?
   Family tracing, continuation/prosecution history mapping, and citation-based adjacency analysis.

5. What minimum inputs are needed for a complete analysis?
   The full claim set plus the patent’s bibliographic/technical identifiers (drug/compound, assignee, priority and filing dates, and CPC/IPC or equivalent classification).

[1]

Drugs Protected by US Patent 3,644,630

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 3,644,630

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	297936
Belgium	756975
Canada	933864
Cyprus	760
Germany	2049112